Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease

American Journal of Cardiology

Volumn 91, Issue 1, 2003, Pages 33-41

  Schneck, Dennis W ^a,b,c,d   Knopp, Robert H ^a,b,c,d   Ballantyne, Christie M ^a,b,c,d   McPherson, Ruth ^a,b,c,d   Chitra, Rohini R ^a,b,c,d   Simonson, Steven G ^a,b,c,d  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ASTHENIA; ASTHMA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; ENZYME BLOOD LEVEL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PAIN; PATIENT SELECTION; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINITIS; SIDE EFFECT; SINUSITIS; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; LINEAR MODELS; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 0037223771     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02994-6     Document Type: Article

References (20)

1. Olsson A.G., Pears J., McKellar J., Mizan J., Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol. 88:2001;504-508.
2. Davidson M., Ma P., Stein E.A., Gotto A.M. Jr, Raza A., Chitra R., Hutchinson H. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 89:2002;268-275.
3. Peters J.R., Quiter E.S., Brekke M.L., Admire J., Brekke M.J., Mullis R.M., Hunninghake D.B. The Eating Pattern Assessment Tool a simple instrument for assessing dietary fat and cholesterol intake . J Am Diet Assoc. 94:1994;1008-1013.
4. Myers G.L., Cooper G.R., Winn C.L., Smith S.J. The Centers for Disease Control-National Heart, Lung, and Blood Institute Lipid Standardization Program an approach to accurate and precise lipid measurements . Clin Lab Med. 9:1989;105-135.
5. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;449-502.
6. Montgomery D.C. Design and Analysis of Experiments. 2nd Ed:1984;10-115 John Wiley & Sons, New York.
7. McTaggart F., Buckett L., Davidson R., Holdgate G., McCormick A., Schneck D., Smith G., Warwick M. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 87:2001;28B-32B.
8. Roberts W.C. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol. 80:1997;106-107.
9. Executive summary of the third report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
10. Wierzbicki A.S., Lumb P.J., Chik G., Crook M.A. Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia. Int J Clin Pract. 53:1999;609-611.
11. Illingworth D.R.Crouse J.R. III, Hunninghake D.B., Davidson M.H., Escobar I.D., Stalenhoef A.F., Paragh G., Ma P.T., Liu M., Melino M.R., et al. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin. 17:2001;43-50.
12. Kastelein J.J., Isaacsohn J.L., Ose L., Hunninghake D.B., Frohlich J., Davidson M.H., Habib R., Dujovne C.A., Crouse J.R., Liu M., et al. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol. 86:2000;221-223.
13. Oram J.F., Yokoyama S. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res. 37:1996;2473-2491.
14. Fodor J.G., Frohlich J.J., Genest J.J.G. Jr, McPherson P.R. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. Can Med Assoc J. 162:2000;1441-1447.
15. Gotto A.M. Jr, Whitney E., Stein E.A., Shapiro D.R., Clearfield M., Weis S., Jou J.Y., Langendorfer A., Beere P.A., Watson D.J., Downs J.R., de Cani J.S. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 101:2000;477-484.
16. Walldius G., Jungner I., Holme I., Aastveit A., Kolar W., Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study) a prospective study . Lancet. 358:2001;2026-2033.
17. Lipid Research Clinics Program. Manual of Laboratory Operations: Lipid and Lipoprotein Analysis. Washington, DC: US Dept of Health, Education and Welfare. Publication NIH 75-628, 1982.
18. Pedersen T.R., Olsson A.G., Faergeman O., Kjekshus J., Wedel H., Berg K., Wilhelmsen L., Haghfelt T., Thorgeirsson G., Pyorala K., et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 97:1998;1453-1460.
19. Ballantyne C.M., Andrews T.C., Hsia J.A., Kramer J.H.Shear C. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels . Am J Cardiol. 88:2001;265-269.
20. Knopp R.H. Drug treatment of lipid disorders. N Engl J Med. 341:1999;498-511.